FDA goes to work on Merck's app for new allergy treatment; Oncolytics shares jump;

 @FierceBiotech: From FierceBiotechResearch.com: New drug could combat resistant #malaria strains. Story | Follow @FierceBiotech

@JohnCFierce: 3 yrs after its first CRL, A.P. Pharma gets another. Insists it can do a quick turnaround, but wrong again on FDA: News | Follow @JohnCFierce

@RyanMFierce: With big RNA deal, AstraZeneca's Soriot signals yen for risky science. More | Follow @RyanMFierce

> The FDA has begun a review of Merck's ($MRK) new treatment for grass pollen allergy, which is designed to block symptoms over time rather than just temporarily stop the sneezing, as current treatments do. The company, which mounted a slate of studies to set up an approval for a mass market, says it expects to get a decision from regulators in the first quarter of 2014. Story

> Shares of Canada's Oncolytics Biotech ($ONCY) jumped on their claim that a mid-stage study of the lung cancer drug Reolysin proved positive. Story

Medical Device News

 @FierceMedDev: CMO adds 200 medical device jobs in Ireland. Report | Follow @FierceMedDev

 @MarkHFierce: A new FMD feature--this week in FDA med tech violations, the device industry's police blotter. More | Follow @MarkHFierce

 @DamianFierce: Abbott won the FDA's OK for a diagnostic that detects birth defects and testicular cancer progress. News | Follow @DamianFierce

> T2 reels in $40M Series E for Candida assay trial and launch. Article

> U.K.'s Consort Medical mulls Dx expansion. Report

> Bacterin 2012 revenue climbs but losses also grow. Item

Pharma News

@FiercePharma: Conquering the complexities of biologics to get to biosimilars. Special report | Follow @FiercePharma

@EricPFierce: Alexion files 8-K saying FDA is not impressed with its manufacturing at its Rhode Island plant. 8-K filing | Follow @EricPFierce

> Rose-colored glasses off for many of 2012's new drugs, report shows. More

> Drugstores push for access to secret PBM pricing-and-reimbursement info. Story

Vaccines News

> GSK vaccine plant helps U.S. arm for biodefense. Report

> Taboo topics: Sex, politics, religion... and vaccines? Article

> Swedish study adds to data linking GSK vax to narcolepsy. Item

> FDA moves decision day for GSK pandemic vaccine, but why? More

Pharma Manufacturing News

> Alexion gets warning letter for Soliris plant. Report

> FDA lifts ban on some Aurobindo antibiotics. News

> Injection point: BD, Teva, Hikma target sterile injectables. Story

> GSK gets OK for $91M vaccine plant with Texas A&M. Article

And Finally… Investigators at Northwestern Medicine say they have ID'd a component of the herpes virus that "hijacks" machinery inside human cells, allowing the virus to rapidly and successfully invade the nervous system upon initial exposure. Release


Suggested Articles

Biogen will develop a gene therapy with the goal of preserving and possibly restoring vision in patients with PRPF31-mutated retinitis pigmentosa.

A month after moving its COVID-19 antibody cocktail into human trials, Regeneron is testing the drug's ability to ward off COVID-19 infection.

Short reports are nothing new, but the aggressive “I’m coming after you” PR from Applied Therapeutics certainly is.